DTech Liquidating

DTech Liquidating R&D / Revenue

Delisted

The R&D to Revenue Ratio of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 99.63 %. In the previous year, R&D to Revenue Ratio was 165.63 % — a change of -39.85% (lower).

R&D / Revenue

99.63 %

YoY

-39.85%

Last updated:

R&D to Revenue Ratio of DTech Liquidating is 2023 99.63 % . R&D to Revenue Ratio of DTech Liquidating was 2022 165.63 % . It decreases by -39.85% lower compared to the previous year.

The DTech Liquidating R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2019
74.40 USD
Jan 1, 2020
89.81 USD
Jan 1, 2021
137.33 USD
Jan 1, 2022
165.63 USD
Jan 1, 2023
99.63 USD
The DTech Liquidating R&D / Revenue history
YEARR&D / RevenueYoY
99.63 %-39.85%
165.63 %+20.61%
137.33 %+52.91%
89.81 %+20.71%
74.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

R&D to Revenue Ratio of DTech Liquidating is 99.63 % in 2023.

R&D to Revenue Ratio of DTech Liquidating changed from 165.63 % to 99.63 %, representing a -39.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's DTech Liquidating with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — DTech Liquidating

All Key Metrics — DTech Liquidating